BioXcel Therapeutics, Inc. Contracts & Agreements
73 Contracts & Agreements
- Business Finance (29 contracts)
- Business Operations (3)
- Human Resources (34)
- Intellectual Property (1)
- Real Estate (2)
- Uncategorized (4)
- Underwriting Agreement, dated November 22, 2024, between the Company and Canaccord Genuity LLC (Filed With SEC on November 25, 2024)
- Form of Pre-funded Warrant (Filed With SEC on November 25, 2024)
- Form of Warrant (Filed With SEC on November 25, 2024)
- Form of New Warrant (Filed With SEC on November 21, 2024)
- Form of Third Amended and Restated Registration Rights Agreement, among the Company and Oaktree-TCDRS Strategic Credit, LLC, Oaktree-Forrest Multi-Strategy, LLC, Oaktree-TBMR... (Filed With SEC on November 21, 2024)
- Addendum to Employment Agreement – Vimal Mehta (Filed With SEC on November 14, 2024)
- Addendum to Employment Agreement – Vince O'Neill (Filed With SEC on November 14, 2024)
- Addendum to Employment Agreement – Frank Yocca (Filed With SEC on November 14, 2024)
- Addendum to Employment Agreement – Richard Steinhart (Filed With SEC on November 14, 2024)
- Separation Agreement between BioXcel Therapeutics, Inc. and Matthew Wiley, dated October 3, 2024 (Filed With SEC on October 9, 2024)
- Consulting Agreement between BioXcel Therapeutics, Inc. and Matthew Wiley, dated October 8, 2024 (Filed With SEC on October 9, 2024)
- Amendment No. 1, dated July 11, 2024, to Commercial Supply Agreement, between ARx, LLC and BioXcel Therapeutics, Inc., dated April 1, 2022 (Filed With SEC on August 6, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on March 25, 2024)
- Form of Accompanying Warrant (Filed With SEC on March 25, 2024)
- Securities Purchase Agreement, dated March 25, 2024, between the Company and the Purchasers (Filed With SEC on March 25, 2024)
- Description of the Registrants Securities Registered Under Section 12 of the Exchange Act (Filed With SEC on March 22, 2024)
- Form of Warrant Agreement, dated March 20, 2024 (Filed With SEC on March 22, 2024)
- Second Amended and Restated Registration Rights Agreement, between the Company and the parties thereto, dated March 20, 2024 (Filed With SEC on March 22, 2024)
- Fourth Amendment to Credit Agreement and Guaranty, dated March 20, 2024, to the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the borrower,... (Filed With SEC on March 22, 2024)
- Third Amendment to Credit Agreement and Guaranty dated February 12, 2024, which amended the Credit Agreement and Guaranty, dated April 19, 2022, by and among the Company, as the... (Filed With SEC on February 12, 2024)
- Form of Amended and Restated Original Warrant (Filed With SEC on December 6, 2023)
- Form of New Warrant (Filed With SEC on December 6, 2023)
- Amended and Restated Registration Rights Agreement, dated December 5, 2023, among the Company and Oaktree-TCDRS Strategic Credit, LLC, Oaktree-Forrest Multi-Strategy, LLC,... (Filed With SEC on December 6, 2023)
- Waiver and First Amendment to Credit Agreement and Guaranty, by and between the Company, the lenders party thereto and Oaktree Fund Administration LLC dated November 13, 2023 (Filed With SEC on November 14, 2023)
- Non-Compete Agreement, by and among the Company, Dr. Krishnan Nandabalan, InveniAI LLC, Invea Therapeutics, Inc. and the other parties thereto, dated September 19, 2023 (Filed With SEC on September 25, 2023)
- First Amendment to Revenue Interest Financing Agreement, dated August 4, 2022, by and between the Company, the purchasers party thereto and Oaktree Fund Administration, LLC, as... (Filed With SEC on May 9, 2023)
- Employment Agreement, dated July 1, 2022, by and between BioXcel Therapeutics, Inc. and Vincent ONeill, M.D (Filed With SEC on May 9, 2023)
- Form of RSU Agreement pursuant to the OnkosXcel Therapeutics, LLC and OnkosXcel Employee Holdings, LLC Management Incentive Plan (Filed With SEC on May 9, 2023)
- OnkosXcel Therapeutics LLC and OnkosXcel Employee Holdings LLC Management Incentive Plan (Filed With SEC on August 19, 2022)
- Form of Profits Interest Award Agreement under the Management Incentive Plan (Filed With SEC on August 19, 2022)
- BioXcel Trademark License Agreement, between the Company and BioXcel LLC, dated April 9, 2022 (Filed With SEC on May 9, 2022)
- Second Amendment to the Second Amended and Restated Separation and Shared Services Agreement, between the Company and BioXcel LLC, dated April 19, 2022 (Filed With SEC on May 9, 2022)
- Form of Warrant (Filed With SEC on April 19, 2022)
- Registration Rights Agreement, dated April 19, 2022, among the Company and Oaktree-TCDRS Strategic Credit, LLC, Oaktree-Forrest Multi-Strategy, LLC, Oaktree-TBMR Strategic Credit... (Filed With SEC on April 19, 2022)
- Employment Agreement between Matthew Wiley and BioXcel Therapeutics, Inc., dated January 12, 2022 (Filed With SEC on March 11, 2022)
- Separation Agreement and General Release between Reina Benabou and BioXcel Therapeutics, Inc., dated July 28, 2021 (Filed With SEC on August 10, 2021)
- Underwriting Agreement, dated June 22, 2021, among the Company, the Selling Stockholder and BofA Securities, Inc., as representative of the underwriters named therein (Filed With SEC on June 25, 2021)
- Open Market Sale Agreement, dated as of May 10, 2021, by and between BioXcel Therapeutics, Inc. and Jefferies LLC (Filed With SEC on May 10, 2021)
- First Amendment to Second Amended and Restated Separation and Shared Services Agreement, dated March 3, 2021, by and between BioXcel LLC and BioXcel Therapeutics Inc (Filed With SEC on March 12, 2021)
- Employment Agreement between Javier Rodriguez and BioXcel Therapeutics, Inc., dated February 15, 2021 (Filed With SEC on March 12, 2021)
- First Amendment, dated August 19, 2020, to Lease Agreement, dated as of August 20, 2018, by and between Fusco Harbour Associates, LLC, as Landlord, and BioXcel Therapeutics, Inc.,... (Filed With SEC on November 12, 2020)
- BioXcel Therapeutics, Inc. 2020 Incentive Award Plan and forms of award agreements thereunder (Filed With SEC on August 14, 2020)
- Employment Agreement between William Kane and BioXcel Therapeutics, Inc., dated May 15, 2020 (Filed With SEC on August 14, 2020)
- Employment Agreement between Reina Benabou and BioXcel Therapeutics, Inc., dated June 21, 2020 (Filed With SEC on August 14, 2020)
- Underwriting Agreement, dated July 28, 2020, among the Company, the Selling Stockholders and BofA Securities, Inc., as representative of the underwriters named therein (Filed With SEC on July 31, 2020)
- BioXcel Therapeutics, Inc. 2020 Incentive Award Plan (Filed With SEC on May 21, 2020)
- BioXcel Therapeutics, Inc. 2020 Employee Stock Purchase Plan (Filed With SEC on May 21, 2020)
- Non-Employee Director Compensation Program (Filed With SEC on May 12, 2020)
- Description of the Registrants Securities Registered Under Section 12 of the Exchange Act (Filed With SEC on March 9, 2020)
- Second Amended and Restated Separation and Shared Services Agreement, dated March 6, 2020, by and between BioXcel Corporation and BioXcel Therapeutics, Inc (Filed With SEC on March 9, 2020)
- Underwriting Agreement, dated February 19, 2020, among the Company and BofA Securities, Inc., as representative of the underwriters named therein (Filed With SEC on February 21, 2020)
- Purchase Agreement, dated February 18, 2020, among the Company and BioXcel Corporation (Filed With SEC on February 21, 2020)
- Underwriting Agreement, dated September 26, 2019, between the Company and BMO Capital Markets Corp., as representative of the underwriters named therein (Filed With SEC on September 27, 2019)
- Open Market Sale Agreement, dated as of May 20, 2019, by and between BioXcel Therapeutics, Inc. and Jefferies LLC (Filed With SEC on May 20, 2019)
- Clinical Trial Collaboration Agreement, dated September 21, 2018, by and between BioXcel Therapeutics, Inc. and Nektar Therapeutics (Filed With SEC on November 9, 2018)
- Lease Agreement, dated as of August 20, 2018, by and between Fusco Harbour Associates, LLC, as Landlord, and BioXcel Therapeutics, Inc., as Tenant (Filed With SEC on August 23, 2018)
- Executive Employment Agreement, dated June 1, 2018, by and between BioXcel Therapeutics, Inc. and Dr. Vincent ONeill, M.D (Filed With SEC on June 7, 2018)
- Executive Employment Agreement, by and between BioXcel Therapeutics, Inc. and Vimal Mehta (Filed With SEC on March 13, 2018)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on March 5, 2018)
- Form of Underwriting Agreement (Filed With SEC on February 12, 2018)
- Grid Note, dated June 30, 2017 (Filed With SEC on February 12, 2018)
- Amended and Restated Separation and Shared Services Agreement, effective November 7, 2017, by and between BioXcel Corporation and BioXcel Therapeutics, Inc (Filed With SEC on February 12, 2018)
- Amended and Restated Asset Contribution Agreement, effective November 7, 2017, by and between BioXcel Corporation and BioXcel Therapeutics, Inc (Filed With SEC on February 12, 2018)
- 2017 Equity Incentive Plan (Filed With SEC on February 12, 2018)
- Form of Incentive Stock Option Agreement under the 2017 Equity Incentive Plan (Filed With SEC on February 12, 2018)
- Form of Non-Statutory Stock Option Agreement under the 2017 Equity Incentive Plan (Filed With SEC on February 12, 2018)
- Form of Indemnification Agreement with directors and executive officers (Filed With SEC on February 12, 2018)
- Employment Agreement, effective September 1, 2014, by and between BioXcel Corporation and Vimal Mehta (Filed With SEC on February 12, 2018)
- Form of Stock Purchase Agreement for September and October 2017 and January and February 2018 Private Placements (Filed With SEC on February 12, 2018)
- First Amendment to Employment Agreement, dated December 21, 2017, by and between BioXcel Corporation and Vimal Mehta (Filed With SEC on February 12, 2018)
- Form of Employment Agreement by and between BioXcel Therapeutics, Inc. and Vimal Mehta, to be effective on the effective date of the registration statement (Filed With SEC on February 12, 2018)
- Employment Agreement, dated February 12, 2018, by and between BioXcel Therapeutics, Inc. and Frank Yocca (Filed With SEC on February 12, 2018)
- Employment Agreement, effective October 2, 2017, by and between BioXcel Therapeutics, Inc. and Richard Steinhart (Filed With SEC on February 12, 2018)